Product Description
Mechanisms of Action: AT1 Inhibitor
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Trevena
Company Location: CHESTERBROOK PA 19087
Company CEO: Carrie L. Bourdow
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Heart Failure
Phase 1: Kidney Diseases|Heart Failure
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CP120027.1002 | P1 |
Completed |
Kidney Diseases|Heart Failure |
2012-05-01 |
|
2010-020376-37 | P2 |
Completed |
Heart Failure |
2012-04-06 |
|
CP120027.2001 | P2 |
Completed |
Heart Failure |
2012-03-01 |